Company Overview
Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a molecular diagnostics company for developing a non invasive urine based prognostic test for progression to aggressive prostate cancer. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Why Investors Should Care
Generates a return on equity of 51.9%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 31.7%.
Recent Developments
- Dec 2025 Revenue of $43.78M (-28.9% YoY); net profit $-37.38M.
- Trailing 12 Months Year-on-year growth — revenue -28.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -11.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -11.20% |
| 1 Year: | -28.87% |
Stock Price Performance
| 1 Year: | +1,440.00% |
| 6 Months: | +1,214.63% |
| 3 Months: | +1,638.71% |
| 1 Month: | +2,529.27% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross9d ago
- RSI (14)75.96 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 51.9%.
- Healthy ROCE of 31.7%.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -11.2% CAGR over 5 years.
- RSI at 76 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TRIB Trinity Biotech plc | 10.78 | -0.18 | $7.28M | 0.00% | 31.67% | 51.92% | -11.20% | - |
| 2 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 3 | WAT Waters Corporation SPX | 400.00 | 50.96 | $39.27B | 0.00% | 20.92% | 5.21% | 4.60% | 2.80% |
| 4 | ZTS Zoetis Inc. SPX | 74.39 | 12.20 | $31.19B | 2.74% | 27.18% | 67.75% | 5.92% | 18.61% |
| 5 | ZBH Zimmer Biomet Holdings, Inc. SPX | 98.16 | 25.43 | $18.99B | 1.02% | 6.61% | 6.07% | 4.50% | -0.54% |
| 6 | BTSG BrightSpring Health Services, Inc. R2K | 59.71 | 77.55 | $11.72B | 0.00% | 6.47% | 9.23% | 18.69% | - |
| 7 | NUVL Nuvalent, Inc. R2K | 123.96 | -20.46 | $9.12B | 0.00% | -31.35% | -41.19% | - | - |
| 8 | IBRX ImmunityBio, Inc. R2K | 7.17 | -8.44 | $7.51B | 0.00% | -58.17% | 70.21% | 54.76% | - |
| 9 | BLTE Belite Bio, Inc | 158.50 | -62.16 | $6.35B | 0.00% | -10.07% | -18.93% | - | -171.21% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 |
|---|---|
| Revenue | 15.86M |
| Cost of Revenue | 10.98M |
| Gross Profit | 4.88M |
| Operating Expenses | 13.44M |
| Operating Income | -8.56M |
| EBITDA | -9.60M |
| Interest Expense | 5.78M |
| Pretax Income | -15.80M |
| Tax Provision | 585.00K |
| Net Income | -16.96M |
| Diluted EPS | -38.37 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 62.52M | 56.83M | 61.55M | 43.78M |
| Cost of Revenue | - | 45.25M | 37.38M | 40.11M | 26.90M |
| Gross Profit | - | 17.27M | 19.45M | 21.44M | 16.89M |
| Operating Expenses | - | 30.78M | 35.39M | 35.15M | 28.30M |
| Operating Income | - | -13.51M | -15.94M | -13.70M | -11.42M |
| EBITDA | - | -29.91M | -25.00M | -16.91M | -21.38M |
| Interest Expense | - | 11.53M | 10.15M | 11.96M | 13.11M |
| Pretax Income | - | -43.78M | -36.93M | -30.73M | -37.18M |
| Tax Provision | - | -194.00K | -59.00K | 486.00K | 199.00K |
| Net Income | - | -41.01M | -24.02M | -31.79M | -37.38M |
| Diluted EPS | 6.00 | -182.40 | -480.00 | -53.10 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 92.10M | 59.44M | 103.29M | 105.17M |
| Current Assets | - | 46.67M | 39.04M | 41.12M | 35.90M |
| Cash & Equivalents | - | 6.58M | 3.69M | 5.17M | 5.14M |
| Inventory | - | 22.50M | 19.93M | 19.37M | 18.83M |
| Receivables | - | 12.62M | 10.70M | 13.42M | 9.36M |
| Total Liabilities | - | 94.28M | 83.38M | 138.47M | 177.15M |
| Current Liabilities | - | 17.34M | 15.04M | 32.09M | 141.21M |
| Long Term Debt | - | 58.05M | 54.65M | 87.79M | 16.33M |
| Total Debt | - | 72.20M | 67.43M | 100.76M | 137.98M |
| Total Equity | - | -2.18M | -23.95M | -35.18M | -71.98M |
| Shares Outstanding | - | 164.99M | 165.87M | 371.75M | 386.76M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -921.00K | -11.56M | -4.19M | -5.93M |
| Investing Cash Flow | - | -5.98M | 24.76M | -22.97M | -6.22M |
| Financing Cash Flow | - | -12.32M | -16.04M | 28.81M | 12.05M |
| Capital Expenditure | - | -5.98M | -2.70M | -10.06M | -6.22M |
| Free Cash Flow | - | -6.90M | -14.26M | -14.26M | -12.15M |
| Net Change in Cash | - | -19.22M | -2.84M | 1.65M | -100.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 27.6% | 34.2% | 34.8% | 38.6% |
| Operating Margin % | - | -21.6% | -28.1% | -22.3% | -26.1% |
| Net Margin % | - | -65.6% | -42.3% | -51.6% | -85.4% |
| ROE % | - | 1,884.6% | 100.3% | 90.4% | 51.9% |
| ROCE % | - | -18.1% | -35.9% | -19.2% | 31.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Hunter Associates Investment Management LLC | 3.27% | 22.04K | $245.19K |
| 2 | Yorkville Advisors Global, LP | 1.11% | 7.50K | $83.44K |
| 3 | Williams & Novak, LLC | 0.69% | 4.68K | $52.12K |
| 4 | Virtu Financial LLC | 0.13% | 889 | $9.89K |
| 5 | Moss Adams Wealth Advisors LLC | 0.13% | 856 | $9.52K |
| 6 | Inspirion Wealth Advisors LLC | 0.12% | 833 | $9.27K |
| 7 | Cambridge Investment Research Advisors Inc. | 0.11% | 743 | $8.27K |
| 8 | Raymond James Financial, Inc. | 0.10% | 677 | $7.53K |
| 9 | Renaissance Technologies, LLC | 0.09% | 592 | $6.59K |
| 10 | Becker Capital Management Inc. | 0.09% | 600 | $6.67K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TRIB
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
European equities traded in the US as American depositary receipts started the week off lower late M
European Equities Traded in the US as American Depositary Receipts Track Sharply Higher in Thursday Trading
European equities traded in the US as American depositary receipts were tracking sharply higher late
European Equities Traded in US as ADRs Ease in Tuesday Trading
European equities traded in the US as American depositary receipts eased late Tuesday morning with t
European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading
European equities traded in the US as American depositary receipts were tracking lower late Thursday
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
European equities traded in the US as American depositary receipts were tracking higher late Wednesd
Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology
- Strategic collaboration and equity investment will combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's innovative intradermal drug delivery technology to develop next-generation metabolic health solut…
TRIB — Frequently Asked Questions
What is the current share price of Trinity Biotech plc (TRIB)?
As of 2026-08-05 17:25 PDT, Trinity Biotech plc (TRIB) trades at $10.78 on NasdaqGS. Its 52-week range is $0.34 to $13.18.
What is the market capitalisation of TRIB?
Trinity Biotech plc (TRIB) has a market capitalisation of $7.28M on NasdaqGS.
What is the P/E ratio of TRIB?
TRIB trades at a trailing price-to-earnings (P/E) ratio of -0.18. The industry average P/E is 25.51. Its price-to-book (P/B) ratio is -0.10.
What is the return on equity (ROE) of TRIB?
TRIB has a return on equity (ROE) of 51.92%. Its return on capital employed (ROCE) is 31.67%.
Is TRIB a good stock to buy?
This page provides a data-driven analysis of Trinity Biotech plc (TRIB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.